Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dianne L Newton

Showing results (1-10 of 27) with videos related to

Pageof 3
Sort By:
Molecular Biotechnology|March 6, 2002
Preparation of recombinant RNase single-chain antibody fusion proteinsDianne L Newton, Susanna M Rybak
Methods in Molecular Biology (Clifton, N.J.)|March 3, 2009
Anti-CD22 Onconase: preparation and characterizationDianne L Newton, Luke H Stockwin, Susanna M Rybak
Expert Review of Proteomics|August 9, 2011
Challenges in plasma membrane phosphoproteomicsBenjamin C Orsburn, Luke H Stockwin, Dianne L Newton
Journal of Molecular Biology|March 28, 2002
Crystallographic and functional studies of a modified form of eosinophil-derived neurotoxin (EDN) with novel biological activitiesChangsoo Chang, Dianne L Newton, Susanna M Rybak, et al.
Methods in Molecular Biology (Clifton, N.J.)|November 5, 2002
Construction and characterization of RNase-based targeted therapeuticsDianne L Newton, Junichiro Futami, Dale Ruby, et al.
BMC Cancer|February 24, 2009
ARC (NSC 188491) has identical activity to Sangivamycin (NSC 65346) including inhibition of both P-TEFb and PKCLuke H Stockwin, Sherry X Yu, Howard Stotler, et al.
Chemistry & Biology|February 8, 2003
RNA cleavage and inhibition of protein synthesis by bleomycinAnil T Abraham, Jih-Jing Lin, Dianne L Newton, et al.
British Journal of Haematology|February 24, 2005
Targeting malignant B-cell lymphoma with a humanized anti-CD22 scFv-angiogenin immunoenzymeJürgen Krauss, Michaela A E Arndt, Bang K Vu, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 20, 2005
A dimeric angiogenin immunofusion protein mediates selective toxicity toward CD22+ tumor cellsMichaela A E Arndt, Jürgen Krauss, Bang K Vu, et al.
Leukemia & Lymphoma|August 1, 2002
Specifically targeting the CD22 receptor of human B-cell lymphomas with RNA damaging agents: a new generation of therapeuticsMiriam Hursey, Dianne L Newton, Hans J Hansen, et al.
Pageof 3

Showing results (1-10 of 27) with videos related to

Sort By:
Pageof 3
Molecular Biotechnology|March 6, 2002
Preparation of recombinant RNase single-chain antibody fusion proteinsDianne L Newton, Susanna M Rybak
Methods in Molecular Biology (Clifton, N.J.)|March 3, 2009
Anti-CD22 Onconase: preparation and characterizationDianne L Newton, Luke H Stockwin, Susanna M Rybak
Expert Review of Proteomics|August 9, 2011
Challenges in plasma membrane phosphoproteomicsBenjamin C Orsburn, Luke H Stockwin, Dianne L Newton
Journal of Molecular Biology|March 28, 2002
Crystallographic and functional studies of a modified form of eosinophil-derived neurotoxin (EDN) with novel biological activitiesChangsoo Chang, Dianne L Newton, Susanna M Rybak, et al.
Methods in Molecular Biology (Clifton, N.J.)|November 5, 2002
Construction and characterization of RNase-based targeted therapeuticsDianne L Newton, Junichiro Futami, Dale Ruby, et al.
BMC Cancer|February 24, 2009
ARC (NSC 188491) has identical activity to Sangivamycin (NSC 65346) including inhibition of both P-TEFb and PKCLuke H Stockwin, Sherry X Yu, Howard Stotler, et al.
Chemistry & Biology|February 8, 2003
RNA cleavage and inhibition of protein synthesis by bleomycinAnil T Abraham, Jih-Jing Lin, Dianne L Newton, et al.
British Journal of Haematology|February 24, 2005
Targeting malignant B-cell lymphoma with a humanized anti-CD22 scFv-angiogenin immunoenzymeJürgen Krauss, Michaela A E Arndt, Bang K Vu, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 20, 2005
A dimeric angiogenin immunofusion protein mediates selective toxicity toward CD22+ tumor cellsMichaela A E Arndt, Jürgen Krauss, Bang K Vu, et al.
Leukemia & Lymphoma|August 1, 2002
Specifically targeting the CD22 receptor of human B-cell lymphomas with RNA damaging agents: a new generation of therapeuticsMiriam Hursey, Dianne L Newton, Hans J Hansen, et al.
Pageof 3